|
1
|
International Agency for Research on
Cancer, World Health Organization. Globocan 2008. World Health
Organization. Website. http://globocan.iarc.fr/.
Accessed October 1, 2010
|
|
2
|
Ishii H, Furuse J, Boku N, et al: Phase II
study of gemcitabine chemotherapy alone for locally advanced
pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreas. Cancer: Principles and Practice of
Oncology. De Vita VT, Hellman S and Rosenberg SA: 6th edition.
Lippincott Williams and Wilkins; Philadelphia: pp. 1126–1161.
2001
|
|
4
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs. observation in patients
undergo curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aloia TA, Lee JE, Vauthey JN, et al:
Delayed recovery after pancreaticoduodenectomy: a major factor
impairing the delivery of adjuvant chemotherapy? J Am Coll Surg.
204:347–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandy H, Bruckner H, Cooperman A, Paradiso
J and Kiefer L: Survival advantage of combined chemoradiotherapy
compared with resection as the initial treatment of patients with
regional pancreatic carcinoma. An outcomes trial. Cancer.
89:314–327. 2000. View Article : Google Scholar
|
|
7
|
Ensminger WD, Rosowsky A and Raso V: A
clinical pharmacological evaluation of hepatic arterial infusions
of 5-fluoro-2-deoxyuridine and 5-fluoroufacil. Cancer Res.
38:3784–3792. 1978.PubMed/NCBI
|
|
8
|
Vogl TJ, Schwarz W, Eichler K, et al:
Hepatic intraarterial chemotherapy with gemcitabine in patients
with unresectable cholangiocarcinoma and liver metastases of
pancreatic cancer: a clinical study on maximum tolerable dose and
treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006.
View Article : Google Scholar
|
|
9
|
Tse AN, Wu N, Patel D, Haviland D and
Kemeny N: A phase I study of gemcitabine given via intrahepatic
pump for primary or metastatic hepatic malignancies. Cancer
Chemother Pharmacol. 64:935–944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van Riel JM, Peters GJ, Mammatas LH, et
al: A phase I and pharmacokinetic study of gemcitabine given by
24-h hepatic arterial infusion. Eur J Cancer. 45:2519–2527.
2009.PubMed/NCBI
|
|
11
|
Tajima H, Ohta T, Kitagawa H, et al: Pilot
study of hepatic arterial infusion chemotherapy with gemcitabine
and 5-fluorouracil for patients with postoperative liver metastases
from pancreatic cancer. Exp Therap Med. 2:265–269. 2011. View Article : Google Scholar
|
|
12
|
Nakamura K, Yamaguchi T, Ishihara T, et
al: Phase I trial of oral S-1 combined with gemcitabine in
metastatic pancreatic cancer. Br J Cancer. 92:2134–2139. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ueno H, Okusaka T, Ikeda M, et al: A phase
I study of combination chemotherapy with gemcitabine and oral S-1
for advanced pancreatic cancer. Oncology. 69:421–427. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura K, Yamaguchi T, Ishihara T, et
al: Phase II trial of oral S-1 combined with gemcitabine in
metastatic pancreatic cancer. Br J Cancer. 94:1575–1579.
2006.PubMed/NCBI
|
|
15
|
Ueno H, Ioka T, Ikeda M, et al: Randomized
phase III study of gemcitabine plus S-1 (GS) versus S-1 alone, or
gemcitabine alone in patiens with locally advanced and metastatic
pancreatic cacer in Japan and Taiwan: GEST study. J Clin Oncol.
31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Urata K, Kawasaki S, Matsunami T, et al:
Calculation of child and adult standard liver volume for liver
transplantation. Hepatology. 21:1317–1321. 1995.PubMed/NCBI
|
|
17
|
Tajima H, Ohta T, Kitagawa H, et al:
Hepatic arterial infusion chemotherapy for post-operative liver
metastases from pancreatic cancer in a patient with leukocytopenia:
a case report. Exp Therap Med. 1:987–990. 2010.PubMed/NCBI
|
|
18
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagakawa T, Nagamori M, Futakami F, et al:
Result of extensive surgery for pancreatic carcinoma. Cancer.
77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noto M, Miwa K, Kitagawa H, et al:
Pancreas head carcinoma: frequency of invasion to soft tissue
adherent to the superior mesenteric artery. Am J Surg Pathol.
29:1056–1061. 2005.PubMed/NCBI
|
|
21
|
Homma H, Akiyama T, Mezawa S, et al:
Advanced pancreatic carcinoma showing a complete response to
arterial infusion chemotherapy. Int J Clin Oncol. 9:197–201. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyanishi K, Ishiwatari H, Hayashi T, et
al: A Phase I trial of arterial infusion chemotherapy with
gemcitabine and 5-fluorouracil for unresectable advanced pancreatic
cancer after vascular supply distribution via superselective
embolization. Jpn J Clin Oncol. 38:268–274. 2008. View Article : Google Scholar
|
|
23
|
Kikuchi K and Kanno H: Comparison for
blood levels and clinical effects between tablet and other dosage
forms of 5-fluorouracil (5-FU). Gan To Kagaku Ryoho. 6:559–565.
1979.(In Japanese).
|
|
24
|
Maruyama S, Ando M and Watayo T:
Concentration of 5-FU after hepatic artery infusion chemotherapy
for liver metastases of colorectal cancer. Gan To Kagaku Ryoho.
30:1635–1638. 2003.(In Japanese).
|
|
25
|
Tajima H, Kitagawa H, Tsukada T, et al: A
phase I study of neoadjuvant chemotherapy with gemcitabine plus
oral S-1 for resectable pancreatic cancer. Mol Clin Oncol.
1:768–772. 2013.PubMed/NCBI
|
|
26
|
Nakahira S, Nakamori S, Tsujie M, et al:
Pretratment with S-1, an oral derivative of 5-fluorouracil,
enhances gemcitabine effect in pancreatic cancer xenografts.
Anticancer Res. 28:179–186. 2008.PubMed/NCBI
|
